Almost 40 percent of those with ADNC had limbic-predominant age-related TDP-43 encephalopathy neuropathologic change
MONDAY, June 20, 2022 (HealthDay News) — Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is seen in almost 40 percent of brains with Alzheimer disease neuropathologic change (ADNC), according to a study published online June 13 in Acta Neuropathologica.
Peter T. Nelson, M.D., Ph.D., from the Sanders‑Brown Center on Aging at the University of Kentucky in Lexington, and colleagues compiled neuropathologic, genetic, and clinical data from 13 high-quality community- and population-based longitudinal studies, including a total of 6,196 participants, to examine the prevalence of LATE-NC across the full range of ADNC.
The researchers found that among the 6,125 participants with available CERAD neuritic amyloid plaque score data, 39.4 percent had autopsy-confirmed LATE-NC of any stage. Of the brains with frequent neuritic amyloid plaques, 54.9 percent had comorbid LATE-NC compared with 27.0 percent of brains with no detected neuritic amyloid plaques. Brains with LATE-NC had relatively more severe primary age-related tauopathy in the subset of individuals with Tha1 Aβ phase = 0 (lacking detectable Aβ plaques). Cognition tended to be worse with LATE-NC across the full spectrum of ADNC severity in the 10 cohorts with detailed neurocognitive assessments close to death.
“These data are interpreted to indicate that LATE-NC, with or without comorbid ADNC, is highly prevalent and impactful in persons of advanced age,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians
Brain Abnormalities Identified in Children at Risk for Schizophrenia
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Imaging Turnaround Time Increased From 2023 to 2024